LivaNova plc (LIVN) Tops Q1 EPS by 21c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus

Go back to LivaNova plc (LIVN) Tops Q1 EPS by 21c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus

LivaNova Reports First Quarter 2021 Results

April 28, 2021 5:00 AM EDT

LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.

For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million, an increase of 2.1 percent on a reported basis and a decline of 0.4 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), first quarter 2021 diluted loss per share from continuing operations was $0.61. First quarter 2021 adjusted diluted earnings per share from continuing operations was... More